These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10971234)

  • 1. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease.
    Carty E; MacEy M; Rampton DS
    Aliment Pharmacol Ther; 2000 Sep; 14(9):1169-79. PubMed ID: 10971234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of circulating platelet derived microparticles in Crohn's disease patients.
    Tziatzios G; Polymeros D; Spathis A; Triantafyllou M; Gkolfakis P; Karakitsos P; Dimitriadis G; Triantafyllou K
    Scand J Gastroenterol; 2016 Oct; 51(10):1184-92. PubMed ID: 27191369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease.
    Nikolaus S; Fölscn U; Schreiber S
    Hepatogastroenterology; 2000; 47(31):71-82. PubMed ID: 10690587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds.
    Shaw IS; Jobson BA; Silverman D; Ford J; Hearing SD; Ball D; Johnson E; Day A; Probert CS
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2053-9. PubMed ID: 12452937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
    Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
    Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.
    Shale MJ; Riley SA
    Aliment Pharmacol Ther; 2003 Jul; 18(2):191-8. PubMed ID: 12869079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease.
    Fägerstam JP; Whiss PA; Ström M; Andersson RG
    Inflamm Res; 2000 Sep; 49(9):466-72. PubMed ID: 11071121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelets circulate in an activated state in inflammatory bowel disease.
    Collins CE; Cahill MR; Newland AC; Rampton DS
    Gastroenterology; 1994 Apr; 106(4):840-5. PubMed ID: 8143990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher platelet P-selectin in male patients with inflammatory bowel disease compared to healthy males.
    Fägerstam JP; Whiss PA
    World J Gastroenterol; 2006 Feb; 12(8):1270-2. PubMed ID: 16534883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid.
    Batta AK; Tint GS; Xu G; Shefer S; Salen G
    J Lipid Res; 1998 Aug; 39(8):1641-6. PubMed ID: 9717724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Aminosalicylic acid.
    Iida T; Onodera K; Nakase H
    Nihon Rinsho; 2017 Mar; 75(3):392-397. PubMed ID: 30566780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?
    De Broe ME; Stolear JC; Nouwen EJ; Elseviers MM
    Nephrol Dial Transplant; 1997 Sep; 12(9):1839-41. PubMed ID: 9306332
    [No Abstract]   [Full Text] [Related]  

  • 14. Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents.
    Present DH
    Gastroenterology; 2000 Jul; 119(1):276. PubMed ID: 10928833
    [No Abstract]   [Full Text] [Related]  

  • 15. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Klotz U
    Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
    Edmond LM; Hopkins MJ; Magee EA; Cummings JH
    Inflamm Bowel Dis; 2003 Jan; 9(1):10-7. PubMed ID: 12656132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: Implication in anti-inflammatory actions of 5-aminosalicylic acid.
    Kang S; Kim W; Jeong S; Lee Y; Nam J; Lee S; Jung Y
    Free Radic Biol Med; 2017 Jul; 108():715-724. PubMed ID: 28473247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.
    Metge CJ; Blanchard JF; Peterson S; Bernstein CN
    Am J Gastroenterol; 2001 Dec; 96(12):3348-55. PubMed ID: 11774948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of inflammatory bowel disease.
    Botoman VA; Bonner GF; Botoman DA
    Am Fam Physician; 1998 Jan; 57(1):57-68, 71-2. PubMed ID: 9447214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for inflammatory bowel disease.
    Treat Guidel Med Lett; 2012 Mar; 10(115):19-28. PubMed ID: 22361569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.